Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer-related Molecular Pathways, Cancer Research and Treatments, Ubiquitin and proteasome pathways, and Monoclonal and Polyclonal Antibodies Research.
A druggable conformational switch in the c-MYC transactivation domain
Liquid–Liquid Phase Separation Primes Spider Silk Proteins for Fiber Formation via a Conditional Sticker Domain
Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity
CD36 and LC3B initiated autophagy in B cells regulates the humoral immune response
CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity
Combining native and ‘omics’ mass spectrometry to identify endogenous ligands bound to membrane proteins
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells
A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology
Understanding p53 functions through p53 antibodies
Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage
p53 isoforms regulate premature aging in human cells
Constitutive activation of WASp in X-linked neutropenia renders neutrophils hyperactive
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Stapled peptide design: principles and roles of computation
Drugging the p53 pathway: understanding the route to clinical efficacy
Functionalised staple linkages for modulating the cellular activity of stapled peptides
A unique role for p53 in the regulation of M2 macrophage polarization
A comparison and optimization of methods and factors affecting the transformation of <i>Escherichia coli</i>
Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9
Stapled Peptides with Improved Potency and Specificity That Activate p53